Jade Biosciences (JBIO) entered into a securities purchase agreement for a private investment in public equity financing that is expected to ...
InvestorsHub on MSN
Jade Biosciences Shares Jump 20% After Revealing Promising Autoimmune Therapy and $135 Million Funding Round
Jade Biosciences (NASDAQ:JBIO) shares surged 20% on Tuesday after the clinical-stage biotech company unveiled JADE201, a new potentially best-in-class therapy for autoimmune diseases, alongside news ...
SAN FRANCISCO and VANCOUVER, British Columbia, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“the Company” or “Jade”), (Nasdaq: ...
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations for ...
Jade Biosciences, Inc. (Nasdaq: JBIO), a biotechnology company focused on autoimmune disease therapies, has announced the successful completion of its reverse merger and its debut on Nasdaq, along ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback